Sun Pharma
Sun Pharmaceutical Industries jumps 7% on $11.75 bn Organon & Co. buyout
Mumbai/IBNS: Shares of Sun Pharmaceutical Industries surged over 7% on Monday after the drug major announced the acquisition of US-based global healthcare firm Organon & Co. in one of the largest overseas deals by an Indian company.
$11.75 Billion All-Cash Deal
Sun Pharma will acquire all outstanding shares of Organon at $14 per share in an all-cash transaction, valuing the deal at an enterprise value of $11.75 billion.
Strengthening Global Presence
Organon is a global leader in women’s health, with a portfolio of over 70 products spanning:
- Women’s Health
- General Medicines
- Biosimilars
The company operates across 140 countries, with key markets including the US, Europe, China, Canada, and Brazil.
Robust Manufacturing Network
Organon’s global footprint is supported by six manufacturing facilities across the European Union and emerging markets, enhancing its scale and supply capabilities.
Strategic Fit for Sun Pharma
The acquisition aligns with Sun Pharma’s strategy to expand its Innovative Medicines business.
- Strengthens position in Established Brands / Branded Generics
- Enables entry into biosimilars as a top-10 global player
- Enhances global reach and long-term value creation
Stock Market Reaction
Investor sentiment turned sharply positive following the announcement:
- Shares rose 7.53% on BSE
- Shares gained 7.50% on NSE
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
